TPSD1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL951611	0.58	16/20
SCHEMBL3332397	0.68	15/20
SCHEMBL3335469	0.68	15/20
SCHEMBL3337061	0.56	14/20
SCHEMBL3339780	0.60	10/20
SCHEMBL3339769	0.59	10/20
SCHEMBL3336049	0.54	9/20
SCHEMBL1668497	0.53	9/20
SCHEMBL3328351	0.48	9/20
SCHEMBL3337050	0.53	8/20
SCHEMBL3337054	0.53	8/20
SCHEMBL1668863	0.51	8/20
SCHEMBL389996	0.46	8/20
SCHEMBL1669095	0.53	7/20
SCHEMBL1668474	0.52	7/20
SCHEMBL329382	0.47	7/20
SCHEMBL2344320	0.46	7/20
SCHEMBL3163506	0.43	7/20
SCHEMBL1668904	0.54	6/20
SCHEMBL953680	0.54	6/20

Clinical trials — most relevant to TPSD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.	PHASE4	RECRUITING
Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients	PHASE2/PHASE3	COMPLETED
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis	PHASE3	COMPLETED
Sumatriptan as Treatment for Post-traumatic Headache	PHASE2	COMPLETED
Effects of Anti-TSLP in Patients With Asthma	PHASE2	COMPLETED
Topical Aprepitant in Prurigo Patients	PHASE2	COMPLETED
Midostaurin in Indolent Systemic Mastocytosis	PHASE2	UNKNOWN
Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients	PHASE2	UNKNOWN
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis	PHASE2	COMPLETED
Safety and Preliminary Efficacy of Endoscopic Submucosal Injection of Hyaluronic Acid Into the Bladder Wall in Patients With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)	PHASE1	NOT_YET_RECRUITING
Sumatriptan and Glucose	EARLY_PHASE1	UNKNOWN
Investigation of the Frequency of Hereditary Hyper Alpha-tryptasemia in Patients With Elevated Basal Tryptasemia	nan	ACTIVE_NOT_RECRUITING
Mast Cell Activation Test in Allergic Disease	nan	COMPLETED
Role of Tryptase Levels in Patients With Stable Coronary Artery Disease.	nan	RECRUITING
Cause and Natural Course of Pediatric-Onset Mastocytosis	nan	COMPLETED
Persistence of Sensitization to Contrast Media	nan	NOT_YET_RECRUITING
Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome	nan	WITHDRAWN
Perioperative Anaphylaxis in Patients Attending University Hospitals (Egypt - UK).	nan	COMPLETED
The Utility of Serum Tryptase in the Diagnosis of Shrimp- Induced Anaphylaxis	nan	COMPLETED
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
Tryptase Level as a Marker of Complications in Transcatheter Aortic Valve Replacement	nan	UNKNOWN
Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations	nan	COMPLETED
Cause of Unexplained Anaphylaxis	nan	ACTIVE_NOT_RECRUITING
Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia	nan	WITHDRAWN
Effect of FODMAPs on Mucosal Inflammation in IBS Patients	nan	UNKNOWN
Allergy and Immunology Natural History Study	nan	RECRUITING
Assessment of Burden Disease in Patients With Mast Cell Disorders	nan	UNKNOWN
Are Mast Cells Involved in Autoinflammatory Diseases	nan	NOT_YET_RECRUITING
Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals	nan	COMPLETED
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TPSD1 binder may also engage these)

Protein	Name	Similarity
P83748	—	0.990	P83748 →
P19236	—	0.985	P19236 →
P15944	—	0.983	P15944 →
Q9QUL7	—	0.982	Q9QUL7 →
Q9N2D1	—	0.982	Q9N2D1 →
Q9XSM2	—	0.981	Q9XSM2 →
P50342	—	0.981	P50342 →
Q9BQR3	—	0.981	Q9BQR3 →
Q9Y6M0	—	0.980	Q9Y6M0 →
O43240	—	0.980	O43240 →
Q7RTY9	—	0.977	Q7RTY9 →
KLK13	Kallikrein-13	0.976	landscape →
Q9ESD1	—	0.975	Q9ESD1 →
Q9QYZ9	—	0.975	Q9QYZ9 →
Q76B45	—	0.973	Q76B45 →
Q8K4I7	—	0.973	Q8K4I7 →
PRSS8	Prostasin	0.973	landscape →
Q6UWY2	—	0.972	Q6UWY2 →
Q7RTY3	—	0.972	Q7RTY3 →
KLK3	Prostate-specific antigen	0.972	landscape →
TPSAB1	Tryptase beta-1	0.972	landscape →
TPSG1	Tryptase gamma	0.972	landscape →
Q14B25	—	0.971	Q14B25 →
Q9ES87	—	0.971	Q9ES87 →
Q61096	—	0.971	Q61096 →
Q6DT45	—	0.971	Q6DT45 →
Q80WM7	—	0.971	Q80WM7 →
Q9GZN4	—	0.971	Q9GZN4 →
Q14B24	—	0.971	Q14B24 →
Q920S2	—	0.970	Q920S2 →